Nurse-Led Care Model Cuts Heart Failure Deaths by 22% in Major India Trial

A nurse-coordinated care model tested across 22 centers in India has cut the risk of death in heart failure patients by 22% over two years, according to results presented at ESC Congress 2026 in Munich and published simultaneously in the journal Circulation on 30 August 2026.

The trial, known as TIME-HF, addresses one of the most persistent gaps in cardiology: patients are routinely under-treated with medications proven to extend their lives, especially outside wealthy countries.

Why the gap matters

Heart failure affects more than 64 million people worldwide, and a specific set of medications, known as guideline-directed medical therapy, has repeatedly been shown to reduce hospitalizations and deaths. Getting patients onto these drugs, and keeping them there, is one of the most effective things cardiology has to offer. For some patients, a procedure helps too: in a German trial, a minimally invasive repair of a leaking tricuspid valve cut the risk of death or hospitalization by 60%.

In practice, that rarely happens. The international REPORT-HF registry, which followed 8,669 patients hospitalized with this type of heart failure in 44 countries and was published in the European Heart Journal in 2022, found that only 19% of patients in low- and middle-income countries left the hospital on all three major drug classes then recommended, compared with 41% in high-income countries. Six months later, the figures were 15% and 37%. Women, patients without health insurance and those without a scheduled follow-up visit were the least likely to be on recommended therapy at target doses.

What the trial changed

TIME-HF enrolled 1,507 adults with reduced heart pumping function (an ejection fraction of 40% or lower). According to the Circulation paper, their average age was 62, 77.6% were men, 57.3% lived in rural areas and 70% had low educational attainment. Centers were randomly assigned to either usual care or a nurse-coordinated model, in which trained nurses worked alongside physicians, used a mobile health app to track symptoms and communicate with patients between visits, and delivered structured counseling on medications and lifestyle changes.

At two years, 37.3% of patients in the nurse-coordinated group were taking all four recommended classes of heart failure drugs, compared with 22.1% in the usual-care group, according to the ESC. That is still far from universal, but it is a substantially larger share of patients receiving proven treatment, in a largely rural population.

The clinical payoff followed the same pattern. In the Circulation paper, the probability of surviving the full two years without a hospital admission was 46.5% in the nurse-coordinated group and 34.7% in the usual-care group, a gain of 11.8 percentage points. There were 163 deaths in the intervention group and 201 in the usual-care group, and after adjustment for the trial design the intervention group had a 22% lower risk of death.

A model built for stretched health systems

Dr. Panniyammakal Jeemon of the Sree Chitra Tirunal Institute for Medical Sciences and Technology in Thiruvananthapuram, who presented the trial, said the data suggest that "a structured, nurse-coordinated, technology-enabled delivery model may offer a practical strategy to improve heart failure outcomes in routine care." He added: "We believe this model is not only relevant to low- and middle-income countries but also to other settings around the world where adherence to guideline-directed medical therapies is suboptimal."

That framing matters because the intervention was designed around constraints common to overstretched health systems: relatively few specialist physicians, patients traveling long distances for follow-up, and limited time for in-person counseling. Rather than requiring more doctors, the model shifts structured, ongoing care onto trained nurses supported by a mobile app, a structure that is easier to scale in places where cardiologists are scarce.

What comes next

Researchers have not yet detailed formal plans to expand the program beyond the 22 trial centers, but the size of the study, its rural and lower-income patient population, and its peer-reviewed publication in Circulation give health systems a concrete, tested model to consider adopting rather than a small pilot result. Questions that remain include how the approach performs outside India, how it holds up over longer follow-up periods, and what it costs to train and deploy nurses at scale.

For a field where the gap between evidence and practice is often the biggest obstacle to saving lives, the trial shows that better-organized, nurse-led follow-up can narrow that gap with a clear, replicable structure.